MASAYA TACHIBANA

Dr. MASAYA TACHIBANA

United Graduate School of Child Development, Osaka University
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
MSMitsuru Shinohara
Mitsuru Shinohara
MTMASAYA TACHIBANA
MASAYA TACHIBANA
TKTakahisa Kanekiyo
Takahisa Kanekiyo
GBGuojun Bu
Guojun Bu
Among the LDL receptor (LDLR) family members, the roles of LDLR-related protein (LRP)1 in the pathogenesis of Alzheimer’s disease (AD), especially late-onset AD, have been the most studied by genetic, neuropathological, and biomarker analyses (clinical studies) or cellular and animal model systems (preclinical studies) over the last 25 years. Although there are some conflicting reports, accumulating evidence from preclinical studies indicates that LRP1 not only regulates the metabolism of amyloid-β peptides (Aβs) in the brain and periphery, but also maintains brain homeostasis, impairment of which likely contributes to AD development in Aβ-independent manners. Several preclinical studies have also demonstrated an involvement of LRP1 in regulating the pathogenic role of apoE, whose gene is the strongest genetic risk factor for AD. Nonetheless, evidence from clinical studies is not sufficient to conclude how LRP1 contributes to AD development. Thus, despite very promising results from preclinical studies, the role of LRP1 in AD pathogenesis remains to be further clarified. In this review, we discuss the potential mechanisms underlying how LRP1 affects AD pathogenesis through Aβ-dependent and -independent pathways by reviewing both clinical and preclinical studies. We also discuss potential therapeutic strategies for AD by targeting LRP1.

1 April 2016 in Stroke
Verified
Journal Article
Closed access
PDF file
YYYu Yamazaki
Yu Yamazaki
DBDarren J. Baker
Darren J. Baker
MTMASAYA TACHIBANA
MASAYA TACHIBANA
CLChia-Chen Liu
Chia-Chen Liu
JDJan M. van Deursen
Jan M. van Deursen
TKTakahisa Kanekiyo
Takahisa Kanekiyo
Background and Purpose—: Age-related changes in the cerebrovasculature, including blood–brain barrier (BBB) disruption, are emerging as potential risks for diverse neurological conditions. Because the accumulation of senescent cells in tissues is increasingly recognized as a critical step leading to age-related organ dysfunction, we evaluated whether senescent vascular cells are associated with compromised BBB integrity. Methods—: Effects of vascular cell senescence on tight junction and barrier integrity were studied using an in vitro BBB model, composed of endothelial cells, pericytes, and astrocytes. In addition, tight junction coverage in microvessels and BBB integrity in BubR1 hypomorphic (BubR1 H/H ) mice, which display senescence cell-dependent phenotypes, were examined. Results—: When an in vitro BBB model was constructed with senescent endothelial cells and pericytes, tight junction structure and barrier integrity (evaluated by transendothelial electric resistance and tracer efflux assay using sodium fluorescein and Evans blue-albumin were significantly impaired. Endothelial cells and pericytes from BubR1 H/H mice had increased senescent-associated β-galactosidase activity and p16 INK4a expression, demonstrating an exacerbation of senescence. The coverage by tight junction proteins in the cortical microvessels were reduced in BubR1 H/H mice, consistent with a compromised BBB integrity from permeability assays. Importantly, the coverage of microvessels by end-feet of aquaporin 4–immunoreactive astrocytes was not altered in the cortex of the BubR1 H/H mice. Conclusions—: Our results indicate that accumulation of senescent vascular cells is associated with compromised BBB integrity, providing insights into the mechanism of BBB disruption related to biological aging.

20 March 2020 in Neuron
Verified
Journal Article
Closed access
NZNa Zhao
Na Zhao
YRYingxue Ren
Yingxue Ren
YYYu Yamazaki
Yu Yamazaki
WQWenhui Qiao
Wenhui Qiao
FLFuyao Li
Fuyao Li
GBGuojun Bu
Guojun Bu

28 January 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
MTMASAYA TACHIBANA
MASAYA TACHIBANA
MHMarie-Louise Holm
Marie-Louise Holm
CLChia-Chen Liu
Chia-Chen Liu
MSMitsuru Shinohara
Mitsuru Shinohara
TATomonori Aikawa
Tomonori Aikawa
TKTakahisa Kanekiyo
Takahisa Kanekiyo
Carrying the ε4 allele of the APOE gene encoding apolipoprotein E (APOE4) markedly increases the risk for late-onset Alzheimer's disease (AD), in which APOE4 exacerbates the brain accumulation and subsequent deposition of amyloid-β (Aβ) peptides. While the LDL receptor-related protein 1 (LRP1) is a major apoE receptor in the brain, we found that its levels are associated with those of insoluble Aβ depending on APOE genotype status in postmortem AD brains. Thus, to determine the functional interaction of apoE4 and LRP1 in brain Aβ metabolism, we crossed neuronal LRP1-knockout mice with amyloid model APP/PS1 mice and APOE3-targeted replacement (APO3-TR) or APOE4-TR mice. Consistent with previous findings, mice expressing apoE4 had increased Aβ deposition and insoluble amounts of Aβ40 and Aβ42 in the hippocampus of APP/PS1 mice compared with those expressing apoE3. Intriguingly, such effects were reversed in the absence of neuronal LRP1. Neuronal LRP1 deficiency also increased detergent-soluble apoE4 levels, which may contribute to the inhibition of Aβ deposition. Together, our results suggest that apoE4 exacerbates Aβ pathology through a mechanism that depends on neuronal LRP1. A better understanding of apoE isoform-specific interaction with their metabolic receptor LRP1 on Aβ metabolism is crucial for defining APOE4-related risk for AD.

30 March 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
NSNobutaka Sakae
Nobutaka Sakae
CLChia-Chen Liu
Chia-Chen Liu
MSMitsuru Shinohara
Mitsuru Shinohara
JFJessica Frisch-Daiello
Jessica Frisch-Daiello
LMLi Ma
Li Ma
TKTakahisa Kanekiyo
Takahisa Kanekiyo
In Alzheimer's disease (AD), the accumulation and deposition of amyloid-β (Aβ) peptides in the brain is a central event. Aβ is cleaved from amyloid precursor protein (APP) by β-secretase and γ-secretase mainly in neurons. Although mutations inAPP,PS1, orPS2cause early-onset familial AD,ABCA7encoding ATP-binding cassette transporter A7 is one of the susceptibility genes for late-onset AD (LOAD), in which itsloss-of-functionvariants increase the disease risk. ABCA7 is homologous to a major lipid transporter ABCA1 and is highly expressed in neurons and microglia in the brain. Here, we show that ABCA7 deficiency altered brain lipid profile and impaired memory in ABCA7 knock-out (Abca7−/−) mice. When bred to amyloid model APP/PS1 mice, plaque burden was exacerbated by ABCA7 deficit.In vivomicrodialysis studies indicated that the clearance rate of Aβ was unaltered. Interestingly, ABCA7 deletion facilitated the processing of APP to Aβ by increasing the levels of β-site APP cleaving enzyme 1 (BACE1) and sterol regulatory element-binding protein 2 (SREBP2) in primary neurons and mouse brains. Knock-down of ABCA7 expression in neurons caused endoplasmic reticulum stress highlighted by increased level of protein kinase R-like endoplasmic reticulum kinase (PERK) and increased phosphorylation of eukaryotic initiation factor 2α (eIF2α). In the brains of APP/PS1;Abca7−/−mice, the level of phosphorylated extracellular regulated kinase (ERK) was also significantly elevated. Together, our results reveal novel pathways underlying the association of ABCA7 dysfunction and LOAD pathogenesis.SIGNIFICANCE STATEMENTGene variants inABCA7encoding ATP-binding cassette transporter A7 are associated with the increased risk for late-onset Alzheimer's disease (AD). Importantly, we found the altered brain lipid profile and impaired memory in ABCA7 knock-out mice. The accumulation of amyloid-β (Aβ) peptides cleaved from amyloid precursor protein (APP) in the brain is a key event in AD pathogenesis and we also found that ABCA7 deficit exacerbated brain Aβ deposition in amyloid AD model APP/PS1 mice. Mechanistically, we found that ABCA7 deletion facilitated the processing of APP and Aβ production by increasing the levels of β-secretase 1 (BACE1) in primary neurons and mouse brains without affecting the Aβ clearance rate in APP/PS1 mice. Our study demonstrates a novel mechanism underlying how dysfunctions of ABCA7 contribute to the risk for AD.

1 March 2013 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
MTMASAYA TACHIBANA
MASAYA TACHIBANA
KKKuriko Kagitani-Shimono
Kuriko Kagitani-Shimono
IMIkuko Mohri
Ikuko Mohri
TYTomoka Yamamoto
Tomoka Yamamoto
WSWakako Sanefuji
Wakako Sanefuji
MTMasako Taniike
Masako Taniike
Objective: Oxytocin (OT) has been a candidate for the treatment of autism spectrum disorders (ASD), and the impact of intranasally delivered OT on ASD has been investigated. However, most previous studies were conducted by single-dose administration to adults; and, therefore, the long-term effect of nasal OT on ASD patients and its effect on children remain to be clarified. Methods: We conducted a singled-armed, open-label study in which OT was administered intranasally over the long term to eight male youth with ASD (10–14 years of age; intelligence quotient [IQ] 20–101). The OT administration was performed in a stepwise increased dosage manner every 2 months (8, 16, 24 IU/dose). A placebo period (1–2 weeks) was inserted before each step. The outcome measures were Autism Diagnostic Observation Schedule – Generic (ADOS-G), Child Behavior Checklist (CBCL), and the Aberrant Behavior Checklist (ABC). In addition, side effects were monitored by measuring blood pressure and examining urine and blood samples. Results: Six of the eight participants showed improved scores on the communication and social interaction domains of the ADOS-G. However, regarding the T-scores of the CBCL and the scores of the ABC, we could not find any statistically significant improvement, although several subcategories showed a mild tendency for improvement. Caregivers of five of the eight participants reported certain positive effects of the OT therapy, especially on the quality of reciprocal communication. All participants showed excellent compliance and no side effects. Conclusions: Although our results on the efficacy of long-term nasal OT therapy still remain controversial, to the best of our knowledge, this is the first report documenting the safety of long-term nasal OT therapy for children with ASD. Even though our data are too preliminary to draw any definite conclusions about efficacy, they do suggest this therapy to be safe, promising, and worthy of a large-scale, double-blind placebo-controlled study.